These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 33591004)

  • 1. von Willebrand Factor Multimer Formation Contributes to Immunothrombosis in Coronavirus Disease 2019.
    Doevelaar AAN; Bachmann M; Hölzer B; Seibert FS; Rohn BJ; Bauer F; Witzke O; Dittmer U; Bachmann M; Yilmaz S; Dittmer R; Schneppenheim S; Babel N; Budde U; Westhoff TH
    Crit Care Med; 2021 May; 49(5):e512-e520. PubMed ID: 33591004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients.
    Joly BS; Darmon M; Dekimpe C; Dupont T; Dumas G; Yvin E; Beranger N; Vanhoorelbeke K; Azoulay E; Veyradier A
    J Thromb Haemost; 2021 Sep; 19(9):2193-2198. PubMed ID: 34219357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
    Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
    Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
    Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Mező B; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
    Thromb Haemost; 2022 Feb; 122(2):240-256. PubMed ID: 35062036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant: implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment.
    Hori Y; Hayakawa M; Isonishi A; Soejima K; Matsumoto M; Fujimura Y
    Transfusion; 2013 Dec; 53(12):3192-202. PubMed ID: 23560518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond.
    Favaloro EJ; Pasalic L; Henry B; Lippi G
    Am J Hematol; 2021 Aug; 96(8):1049-1055. PubMed ID: 33991361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
    Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
    Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A
    Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Prevention of Congenital Thrombotic Thrombocytopenic Purpura in ADAMTS13 Knockout Mice by Sleeping Beauty Transposon-Mediated Gene Therapy.
    Verhenne S; Vandeputte N; Pareyn I; Izsvák Z; Rottensteiner H; Deckmyn H; De Meyer SF; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2017 May; 37(5):836-844. PubMed ID: 28254814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13.
    Yang J; Wu Z; Long Q; Huang J; Hong T; Liu W; Lin J
    Front Immunol; 2020; 11():610696. PubMed ID: 33343584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Overview of Laboratory Testing for ADAMTS13.
    Favaloro EJ; Pasalic L
    Methods Mol Biol; 2023; 2663():481-486. PubMed ID: 37204731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obstetric outcomes in pregnant COVID-19 women: the imbalance of von Willebrand factor and ADAMTS13 axis.
    Grandone E; Vimercati A; Sorrentino F; Colaizzo D; Ostuni A; Ceci O; Capozza M; Tiscia G; De Laurenzo A; Mastroianno M; Cappucci F; Fischetti L; Margaglione M; Cicinelli E; Nappi L
    BMC Pregnancy Childbirth; 2022 Feb; 22(1):142. PubMed ID: 35189860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Link between von Willebrand factor multimers, relapses and coronary microcirculation in patients with thrombotic thrombocytopenic purpura in remission.
    Di Pasquale I; Budde U; Tona F; Bertomoro A; Lombardi AM; Famoso G; Bertozzi I; Dittmer R; Schneppenheim S; Fabris F
    Thromb Res; 2019 Jan; 173():42-47. PubMed ID: 30471507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
    Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
    Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
    Budde U; Schneppenheim R
    Hamostaseologie; 2014; 34(3):215-25. PubMed ID: 25010251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.
    Philippe A; Gendron N; Bory O; Beauvais A; Mirault T; Planquette B; Sanchez O; Diehl JL; Chocron R; Smadja DM
    Angiogenesis; 2021 Aug; 24(3):407-411. PubMed ID: 33974165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
    Henry BM; Benoit SW; de Oliveira MHS; Lippi G; Favaloro EJ; Benoit JL
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):129-136. PubMed ID: 33270980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
    Tsai HM; Lian EC
    N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
    Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
    N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report.
    Schwaegermann MK; Hobohm L; Rausch J; Reuter M; Griemert TF; Sivanathan V; Falter T; Sprinzl MF; Lackner KJ; Galle PR; Konstantinides S; Theobald M; von Auer C
    Hamostaseologie; 2023 Jun; 43(3):215-218. PubMed ID: 34327693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.